<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01200108</url>
  </required_header>
  <id_info>
    <org_study_id>Acti-AICS-001</org_study_id>
    <nct_id>NCT01200108</nct_id>
  </id_info>
  <brief_title>AKITA Inhaled Steroid Suspension for Inhalation (AICS) in Subjects With Asthma</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate Tolerability, Safety and Efficacy of AKITA Inhaled Steroid Suspension for Inhalation (AICS) in Subjects With Asthma Requiring Chronic Oral Corticosteroid Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Activaero GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Activaero GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of treatment with AICS is weaning from oral corticosteroids, i.e. a reduction of the
      oral corticosteroid dose. An anticipated treatment benefit of AICS is a reduction of oral
      corticosteroid dose and stability/improvement of clinical parameters related to asthma in the
      targeted subject population. Ultimately, the goal is to free subjects with severe asthma from
      the burden of chronic oral steroid therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <number_of_arms>4</number_of_arms>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Budesonide high dose via AKITA (1mg/2ml)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Budesonide low dose via AKITA (0.5mg/2ml)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Budesonide high dose via conventional nebulizer (1mg/2ml)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo via AKITA</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide</intervention_name>
    <arm_group_label>Budesonide high dose via AKITA (1mg/2ml)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide</intervention_name>
    <arm_group_label>Budesonide low dose via AKITA (0.5mg/2ml)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide</intervention_name>
    <arm_group_label>Budesonide high dose via conventional nebulizer (1mg/2ml)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent prior to the performance of any study-related procedures

          -  Age ≥ 18 and ≤ 65 year of age Diagnosis of asthma (ATS definition, either allergic or
             non-allergic) for ≥ 6 months

          -  Asthma treated for at least 3 months with inhaled (ICS) and oral corticosteroids
             (OCS). Exact baseline level will be measured during the screening period by subject
             diary entries

          -  FEV1 ≥ 40% or ≤ 79% predicted at the Screening or Baseline Visit

          -  Documented increase of FEV1 within 15-30 minutes after the use of inhaled Salbutamol
             at the Screening Visit or within 2 years prior to Screening

          -  Mandatory usage of long-acting β-agonists

          -  A negative pregnancy test must be available for any women of childbearing potential at
             screening and, in addition, a negative urine pregnancy test must be present at
             randomization (prior to randomization to one of the treatment groups!)

          -  Women of childbearing potential must agree to use a reliable method of contraception
             from the screening until 4 weeks after study completion or after study drug
             discontinuation in case study drug treatment is stopped prematurely. - In this study,
             hormone-based contraceptives alone are not considered as reliable method

        Exclusion Criteria:

          -  History of allergy or adverse experience with Budesonide

          -  Pregnant women or nursing mothers

          -  Upper respiratory tract infection within 4 weeks of Screening

          -  Emergency room visit for treatment of asthma exacerbation within 4 weeks of Screening

          -  Hospitalization for asthma within 3 months of Screening

          -  Use of anti-IgE, methotrexate, oral gold, Dapsone, or i.v. gamma globulin within 3
             months of Screening

          -  Treatment with other investigational asthma treatment within 30 days prior to
             Screening

          -  Evidence of chronic lung diseases other than asthma, including but not limited to:
             cystic fibrosis, allergic bronchopulmonary aspergillosis (ABPA), COPD, chronic
             bronchitis and emphysema

          -  History of medication noncompliance

          -  History of significant medical illness or condition that in the Investigator's opinion
             places the subject at undue risk by participating in the study

          -  Past episode of anaphylaxis with severe respiratory symptoms

          -  Oral corticosteroid average daily dose exceeding a maximum amount

          -  Currently smoking or history of smoking ≥ 10 pack years

          -  Taking oral or i.v. corticosteroids for any disease indication other than asthma

          -  Abnormal lab values for chemistry tests at Screening that may indicate impaired
             ability to metabolize and/or excrete Budesonide (AST, ALT &gt; 3 times upper limit of
             normal range, serum creatinine &gt; 1.5 times upper limit of normal range)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Kardos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peter Kardos</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>10717</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bonn</city>
        <zip>53119</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bonn</city>
        <zip>53123</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Darmstadt</city>
        <zip>64287</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter, Kardos, MD</name>
      <address>
        <city>Frankfurt</city>
        <zip>60318</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marburg</city>
        <zip>35037</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <zip>80331</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rodgau-Dudenhofen</city>
        <zip>63110</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rüdersdorf</city>
        <zip>15562</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Schwetzingen</city>
        <zip>68723</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Katowice</city>
        <zip>40-752</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kraków</city>
        <zip>31-159</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <zip>20-954</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lódz</city>
        <zip>92-215</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznán</city>
        <zip>60-214</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Skierniewice</city>
        <zip>96-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <zip>50-239</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49074</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Donetsk</city>
        <zip>83099</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kharkiv</city>
        <zip>61124</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyiv</city>
        <zip>03680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vinnytsia</city>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Poland</country>
    <country>Ukraine</country>
  </location_countries>
  <link>
    <url>http://www.activaero.de</url>
    <description>Homepage of the trial sponsor</description>
  </link>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2010</study_first_submitted>
  <study_first_submitted_qc>September 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2010</study_first_posted>
  <last_update_submitted>November 14, 2011</last_update_submitted>
  <last_update_submitted_qc>November 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Thomas Hofmann</name_title>
    <organization>Activaero GmbH</organization>
  </responsible_party>
  <keyword>Severe Asthma, requiring chronic oral steroid use</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

